Good point. My previous imaginary figure of $100M minimum is likely far too low, based on the AmyVid deal. Hopefully it's much more, which would translate to a higher dividend payout to shareholders, in the form of cash and/or shares in the spin-off, or some combination of both.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links